VK2735
What it is
VK2735 is a synthetic peptide developed by Viking Therapeutics that acts as a dual agonist at the glucagon-like peptide-1 (GLP-1) receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor. It belongs to the same broad mechanistic class of dual incretin receptor agonists as tirzepatide, and it is being explored in both a once-weekly subcutaneous form and an oral tablet form.
Research context and categorization
VK2735 falls under the metabolic and weight-regulation category of research compounds. Because it engages two incretin receptor pathways at once, it is commonly discussed in relation to appetite signaling, glucose-dependent insulin release, gastric emptying, and body-weight regulation. In the published Phase 2 VENTURE study and subsequent trial reporting, the subcutaneous form has been investigated for weight reduction over short treatment windows, and a separate oral formulation has been studied in the same context.
These uses are investigational. VK2735 has not completed the full regulatory process, and none of the effects described in trial reporting should be treated as confirmed or approved outcomes. The compound remains in clinical development, and any research framing here reflects what it is studied in the context of, not established benefits.
Status
- Regulatory status: Research-only and investigational. As of 2026, VK2735 is not FDA-approved for any indication and remains in clinical trials, advancing into Phase 3 development.
- Sport status: Not specifically listed by name on the WADA Prohibited List. VK2735 is an investigational compound rather than a named substance. Its dual GLP-1/GIP receptor agonist class has been the subject of ongoing WADA attention and monitoring discussion under the broader area of hormone and metabolic modulators, and status can change from year to year. Anyone in a tested sport should confirm the current WADA Prohibited List and Monitoring Program directly rather than relying on class assumptions.
Reconstitution notes (general)
Lyophilized research peptides are reconstituted by adding bacteriostatic water to the vial. The resulting concentration follows a simple relationship: concentration equals the milligrams of peptide in the vial divided by the millilitres of bacteriostatic water added. For example, a 10 mg vial reconstituted with 2 mL yields 5 mg/mL, while the same vial with 1 mL yields 10 mg/mL. A reconstitution calculator is available at our reconstitution and blend calculators to work out the concentration for a given vial size and water volume.
Dilution and handling notes (compound-specific)
The research-supply form of VK2735 is typically a lyophilized (freeze-dried) powder, most often in vials around 5 mg to 15 mg, with 10 mg being common. Note that VK2735 is also being developed clinically as an oral tablet, but that tablet is a formulated pharmaceutical product and is not the same as a research vial; the reconstitution notes here apply only to lyophilized powder, not to any oral form.
For the injectable peptide form, a common approach is 1 mL to 2 mL of bacteriostatic water per 10 mg vial. Lower water volumes give a higher concentration and a smaller measured volume, while more water gives a lower concentration that is easier to measure precisely. Incretin-class peptides like this one generally dissolve readily and produce a clear, colorless solution. To help this along, add the water slowly down the inner wall of the vial rather than directly onto the powder, then swirl or gently roll the vial. Do not shake vigorously, because agitation can foam the solution and promote peptide aggregation. If a concentrated solution looks slightly hazy or is slow to clear, letting it sit and swirling gently usually resolves it; persistent cloudiness, particulates, or discoloration indicate the solution should not be used.
Handling and storage
Store the reconstituted solution refrigerated at 2 to 8 C and keep it out of direct light. Wipe the rubber stopper with an alcohol swab before each withdrawal, and label the vial with the mix date. A reconstituted peptide is generally treated as usable for roughly a four-week refrigerated window when handled cleanly. Discard the vial if the contents become cloudy or discolored, or if floaters or particulates appear.
Related reading
Tools and supplies
- Reconstitution & blend calculators
- Bacteriostatic Water 30 ml
- Gansulin Metal Reusable Pen
- 3 ml Glass Cartridges (10-pack)
- Complete Starter Kit
For laboratory and research reference only. Educational content, not medical, dosing, injection, or therapeutic guidance, and not intended for human or animal use. Any research uses described are investigational and not confirmed or approved benefits. Confirm anything involving health with a licensed professional. References linked above.